ClearPoint Neuro (CLPT) Competitors $11.78 +0.24 (+2.08%) Closing price 04/15/2025 04:00 PM EasternExtended Trading$11.80 +0.02 (+0.17%) As of 04/15/2025 05:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CLPT vs. CDRE, KMTS, LQDA, TNDM, PLSE, FNA, INMD, BLFS, MDXG, and AORTShould you be buying ClearPoint Neuro stock or one of its competitors? The main competitors of ClearPoint Neuro include Cadre (CDRE), Kestra Medical Technologies (KMTS), Liquidia (LQDA), Tandem Diabetes Care (TNDM), Pulse Biosciences (PLSE), Paragon 28 (FNA), InMode (INMD), BioLife Solutions (BLFS), MiMedx Group (MDXG), and Artivion (AORT). These companies are all part of the "medical equipment" industry. ClearPoint Neuro vs. Cadre Kestra Medical Technologies Liquidia Tandem Diabetes Care Pulse Biosciences Paragon 28 InMode BioLife Solutions MiMedx Group Artivion Cadre (NYSE:CDRE) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap industrials companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, media sentiment, earnings, institutional ownership, community ranking, valuation, dividends and profitability. Which has more risk & volatility, CDRE or CLPT? Cadre has a beta of 1.33, meaning that its share price is 33% more volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.97, meaning that its share price is 3% less volatile than the S&P 500. Do analysts prefer CDRE or CLPT? Cadre currently has a consensus target price of $37.00, indicating a potential upside of 19.61%. ClearPoint Neuro has a consensus target price of $25.00, indicating a potential upside of 112.22%. Given ClearPoint Neuro's higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than Cadre.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadre 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ClearPoint Neuro 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is CDRE or CLPT more profitable? Cadre has a net margin of 6.34% compared to ClearPoint Neuro's net margin of -59.64%. Cadre's return on equity of 12.88% beat ClearPoint Neuro's return on equity.Company Net Margins Return on Equity Return on Assets Cadre6.34% 12.88% 6.06% ClearPoint Neuro -59.64%-62.10%-38.39% Does the MarketBeat Community prefer CDRE or CLPT? ClearPoint Neuro received 9 more outperform votes than Cadre when rated by MarketBeat users. Likewise, 89.29% of users gave ClearPoint Neuro an outperform vote while only 55.17% of users gave Cadre an outperform vote. CompanyUnderperformOutperformCadreOutperform Votes1655.17% Underperform Votes1344.83% ClearPoint NeuroOutperform Votes2589.29% Underperform Votes310.71% Which has preferable earnings and valuation, CDRE or CLPT? Cadre has higher revenue and earnings than ClearPoint Neuro. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Cadre, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCadre$567.56M2.21$38.64M$0.9034.37ClearPoint Neuro$31.39M10.37-$22.09M-$0.70-16.83 Do insiders and institutionals hold more shares of CDRE or CLPT? 44.0% of Cadre shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 37.0% of Cadre shares are owned by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media refer more to CDRE or CLPT? In the previous week, Cadre had 5 more articles in the media than ClearPoint Neuro. MarketBeat recorded 6 mentions for Cadre and 1 mentions for ClearPoint Neuro. ClearPoint Neuro's average media sentiment score of 0.94 beat Cadre's score of 0.71 indicating that ClearPoint Neuro is being referred to more favorably in the news media. Company Overall Sentiment Cadre Positive ClearPoint Neuro Positive SummaryCadre beats ClearPoint Neuro on 11 of the 17 factors compared between the two stocks. Remove Ads Get ClearPoint Neuro News Delivered to You Automatically Sign up to receive the latest news and ratings for CLPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CLPT vs. The Competition Export to ExcelMetricClearPoint NeuroSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$325.51M$4.07B$5.33B$7.57BDividend YieldN/A39.50%5.11%4.33%P/E Ratio-17.0727.6321.7317.81Price / Sales10.3750.20379.1494.58Price / CashN/A51.0838.1534.64Price / Book13.705.826.464.00Net Income-$22.09M$67.09M$3.20B$247.23M7 Day Performance12.08%5.64%6.54%7.26%1 Month Performance-7.97%-3.20%-8.55%-6.26%1 Year Performance109.98%14.87%10.33%-0.18% ClearPoint Neuro Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CLPTClearPoint Neuro2.0839 of 5 stars$11.78+2.1%$25.00+112.2%+110.0%$325.51M$31.39M-17.07110CDRECadre3.4227 of 5 stars$31.24+1.5%$37.00+18.4%-7.8%$1.27B$567.56M37.642,240KMTSKestra Medical TechnologiesN/A$23.83-1.9%$27.67+16.1%N/A$1.18B$45.82M0.00300Earnings ReportQuiet Period ExpirationNews CoverageLQDALiquidia2.2633 of 5 stars$13.83+2.7%$26.63+92.5%-0.6%$1.18B$14.00M-8.4850TNDMTandem Diabetes Care4.2123 of 5 stars$17.03-0.2%$43.88+157.7%-44.4%$1.13B$940.20M-8.822,600News CoveragePositive NewsPLSEPulse Biosciences1.1608 of 5 stars$16.54+3.1%N/A+117.8%$1.11B$700,000.000.00140Positive NewsFNAParagon 281.463 of 5 stars$13.00+0.1%$14.20+9.2%+32.0%$1.09B$256.18M-17.57343,000Short Interest ↓News CoverageHigh Trading VolumeINMDInMode2.2476 of 5 stars$15.08+1.3%$21.25+40.9%-12.9%$1.05B$394.82M6.42480Analyst ForecastNews CoverageBLFSBioLife Solutions2.2077 of 5 stars$22.08+0.8%$31.17+41.2%+43.0%$1.04B$82.25M-20.83440MDXGMiMedx Group3.1856 of 5 stars$6.77-1.0%$12.00+77.3%+7.1%$997.67M$348.88M12.31870Positive NewsAORTArtivion2.5719 of 5 stars$23.15-0.9%$31.40+35.6%+13.1%$973.41M$388.54M-1,157.501,300 Remove Ads Related Companies and Tools Related Companies Cadre Competitors Kestra Medical Technologies Competitors Liquidia Competitors Tandem Diabetes Care Competitors Pulse Biosciences Competitors Paragon 28 Competitors InMode Competitors BioLife Solutions Competitors MiMedx Group Competitors Artivion Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CLPT) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTwo Unmistakable Patterns Return…The signs suggest we're entering one of those rare periods now. That's why Central Banks are buying gold at...Golden Portfolio | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredTariffs. Volatility. Fear. Here’s the Plan.Wall Street's panicking over tariffs. Volatility's back with a vengeance. If you've been glued to the he...Investors Alley | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ClearPoint Neuro, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ClearPoint Neuro With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CLPT Stock Free CLPT Stock Alerts